L-asparaginase is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL). The effectiveness is thought to result from depletion of asparagine in serum and cells. We investigated the clinical response in vivo of 1000 IU/m 2 pegylated (PEG)-asparaginase and its pharmacokinetic, pharmacodynamic and intracellular effects in children with newly diagnosed ALL before start of combination chemotherapy. The in vivo window response was significantly related to immunophenotype and genotype: 26/38 common/pre B-ALL cases, especially those with hyperdiploidy and TELAML1 rearrangement, demonstrated a good clinical response compared to 8/17 T-ALL (P ¼ 0.01) and BCRABL-positive ALL (P ¼ 0.04). A poor in vivo clinical window response was related to in vitro resistance to L-asparaginase (P ¼ 0.02) and both were prognostic factors for long-term event-free survival (hazard ratio 6.4, P ¼ 0.004; hazard ratio 3.7, P ¼ 0.01). After administration of one in vivo dose of PEG-asparaginase no changes in apoptotic parameters or in intracellular levels of twenty amino acids in leukemic cells could be measured, in contradiction to the changes found after in vitro exposure. This may be explained by the rapid removal of apoptotic cells from the circulation in vivo. One additional dose of PEG-asparaginase upfront ALL treatment did not lead to other severe toxicities.
Introduction
L-asparaginase is an effective drug to treat newly diagnosed acute lymphoblastic leukemia (ALL).
1 Prolonged L-asparaginase intensification significantly improved the outcome of ALL patients as was demonstrated in the Dana-Farber Cancer Institute ALL Consortium Protocol 91-01. 2 Several studies have shown that in vitro resistance to this drug is an independent prognostic factor in ALL. [3] [4] [5] [6] [7] [8] Also a poor early in vivo response to L-asparaginase as a single drug has been linked to an unfavorable outcome in pediatric ALL. 9 The administration of L-asparaginase results in the deamination of asparagine into aspartic acid leading to a rapid and complete depletion of serum asparagine, which ultimately affects the intracellular asparagine levels. 10 ,11 L-asparaginase also has 3-4% glutaminase activity leading to serum glutamine depletion. 12 L-asparaginase enzymatic activity should be 4100 IU/l to sufficiently diminish the asparagine serum levels required to induce leukemic cell kill. 13 Amino-acid deficiency impairs protein synthesis and leads to apoptosis and cell death. 14 In vitro studies demonstrated that cellular deprivation of asparagine and glutamine leads to increased levels of asparagine synthetase. 15 This enzyme opposes the action of L-asparaginase and, thereby can rescue cells from the effect of L-asparaginase. 16 Human leukemia cell line studies suggested that only L-asparaginase-resistant cells upregulate the activity of asparagine synthetase. 15 However, we recently demonstrated that upregulation of asparagine synthetase mRNA occurs in both sensitive and in resistant cases within 24 h of in vivo exposure to L-asparaginase. 17 These data imply that mechanisms other than increased expression levels of asparagine synthetase contribute to cellular L-asparaginase resistance.
Recently, gene expression profiling studies by microarray analysis revealed that leukemic cells of L-asparaginase-resistant ALL patients express higher levels of genes involved in protein synthesis than L-asparaginase-sensitive cells. 18 A deficiency in amino acids finally induces apoptosis in malignant cells.
L-asparaginase activates caspase 3 and inactivates poly-ADPribose-polymerase (PARP) in patients leukemic cells and resistance to L-asparaginase is linked to an impaired capacity of cells to trigger the apoptotic pathway. 19 Hypothetically, an altered intracellular amino-acid composition might rescue cells from the effects of L-asparaginase. It is yet unknown whether the amino-acid metabolism of L-asparaginase differs between resistant and sensitive leukemic cells of patients.
In the present study we investigated pharmacokinetic and pharmacodynamic as well as intracellular effects of one in vivo dose of pegylated-L-asparaginase (PEG-asparaginase) in children with newly diagnosed ALL. In vivo response to PEG-asparaginase was monitored by analyzing the decrease in leukemic cells during a therapeutic window of 5 days before start of combination chemotherapy. In vivo response to PEG-asparaginase was compared with the baseline as well as PEGasparaginase-induced changes in serum and intracellular amino-acid levels and with parameters of apoptosis. In vitro resistance to L-asparaginase was determined and compared to the mentioned factors that might influence drug resistance. In addition, the influence of PEG-asparaginase given upfront regular antileukemic treatment was evaluated on the incidence of allergic reactions during treatment and changes in hemostasis.
Methods

Patients and treatment
In close collaboration between our institution and the Dutch Childhood Oncology Group (DCOG), a window study with PEG-asparaginase upfront to the ALL-9 treatment schedule was initiated in July 2000. The ALL-9 protocol was based on the ALL-6 treatment strategy of the DCOG. 20 Children with newly diagnosed ALL and presenting white blood count (WBC)410 Â 10 9 per liter were eligible for the window study with PEG-asparaginase. Patients received a single dose of 1000 IU/m 2 PEG-asparaginase in an 1-h infusion 5 days before starting combination chemotherapy. 21 PEG-asparaginase (Oncaspar), kindly provided by Medac (GmbH, Hamburg, Germany), was used because of its lower immunogenicity than native (unpegylated) L-asparaginase, 22 which was important as native E. coli L-asparaginase (Paronal, four doses of 6000 IU/m 2 on days 29, 33, 36 and 40) was used as part of the regular combination chemotherapy given after the investigational window. After the PEG-asparaginase window, patients were divided into non-high-risk and high-risk criteria. Non-high-risk ALL was defined as WBCo50 Â 10 9 per liter, no mediastinal mass, absence of t(9;22), t(4;11) or other mixed lineage leukemia (MLL) rearrangements, no T-cell phenotype and no central nervous system or testicular involvement. All other leukemias were defined as high risk. All children received the combination induction therapy of dexamethasone, vincristine and intrathecal therapy during the first 4 weeks, and additional daunorubicin only in case of high-risk ALL.
The window study with PEG-asparaginase was approved by the local ethical committee and by the institutional research board of the DCOG. The patient and/or the parents/guardians gave informed consent for this study.
The immunophenotyping and cytogenetic characterizations were performed at the central reference laboratory of the DCOG and at laboratories of the participating centers. B-lineage ALL (CD19 þ , HLA-DR þ ) was classified into the following differentiation stages: proB-ALL cells were CD10 À , cytoplasmic m chain À (cm À ) and surface immunoglobulin À (sIg À ); c-ALL cells were CD10 þ /cm À /sIg À ; pre-B cells were CD10 þ orÀ /cm þ /sIg À .
B-ALL cells characterized by CD10
À /cm À /sIg þ were excluded from the study. Cytogenetic analyses were performed by regular karyotyping and fluorescence in situ hybridization. 23 
Patient samples
Bone marrow and peripheral blood samples were obtained at initial diagnosis of ALL before the administration of PEGasparaginase. Serum and leukemic cells from peripheral blood were collected 1 h after the end of the infusion with PEGasparaginase and thereafter daily during 5 consecutive days till the start of combination chemotherapy at day 0. Mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (density 1.077 g/ml; Lucron bioproducts, Gennep, the Netherlands) as described before. 17 Contaminating nonleukemic cells were removed by immunomagnetic beads as described earlier. 24 All samples contained over 90% of leukemic cells, as determined morphologically on May-Grünwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins.
Clinical response
In correspondence with the definition of the window response to prednison in ALL 25 the clinical window response to PEGasparaginase on day 0 (5 days after the PEG-asparaginase infusion) was defined as good when the number of leukemic cells was o1 Â 10 9 per liter of peripheral blood, as intermediate when leukemic cells were 1-10 Â 10 9 per liter, and as poor when leukemic cells were 410 Â 10 9 per liter.
In vitro cytotoxicity
In vitro L-asparaginase cytotoxicity in leukemic cells taken at initial diagnosis (untreated) was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were exposed to six different concentrations of L-asparaginase (Paronal; Christiaens BV, Breda, the Netherlands) ranging from 0.0032 to 10 IU/ml in duplicate for 4 days. Control cells were cultured without L-asparaginase. After 4 days of incubation at 37 1C in humidified air containing 5% CO 2 , the MTT assay was performed. Drug sensitivity was assessed by the LC 50 , the drug concentration lethal to 50% of the cells. Evaluable assay results were obtained when a minimum of 70% of leukemic cells was present in the control wells after 4 days of incubation and when the control OD was X0.050.
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In vitro sensitivity toward L-asparaginase was defined as LC 50 p0.033 IU/ml, in vitro resistance toward L-asparaginase was defined as LC 50 X0.912 IU/ml, and intermediate sensitive was defined as LC 50 0.033-0.912 IU/ml. 8 As LC 50 values were highly correlated between Paronal and L-asparaginase Medac (Rs 0.93, Po0.002) and between Paronal and PEG-asparaginase (Oncaspar) (Rs 0.86, Po0.002) all consecutive MTT assays were performed using Paronal.
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Apoptotic features
Determination of Annexin V, DIOC 6 , cleaved-caspase-3 and cleaved PARP were performed by fluorescence-activated cell sorting analysis as described earlier. L-asparaginase activity and amino-acid levels in serum Serum levels of L-asparaginase and asparagine, glutamine, aspartic acid and glutamic acid were determined in the laboratory of Prof Dr J Boos (University Children's Hospital Muenster, Department of Pediatric Hematology/Oncology, Germany). Blood samples were taken daily from day À5 to 0, and twice a week from day 0 to 28. L-asparaginase activity was analyzed as described before. 26 After collection serum was isolated by centrifugation and stored immediately at À80 1C; serum levels of asparagine, aspartic acid, glutamine and glutamic acid were performed using high-performance liquid chromatography. 27 The lower limit of detection was 0.2 mM for all amino acids; glutamine levels higher than 250 mM were not further analyzed and reported as 4250 mM. The serum levels of asparagine and the L-asparaginase activity in a part of the patients included in the present study have been published before. 28 
Intracellular amino-acid levels
Intracellular levels of all essential and nonessential amino acids were measured by liquid column chromatography on a Biochrome 20 amino-acid analyzer with ninhydrin detection (Biochrome, Cambridge, UK). Blood samples were taken daily from day -5 at diagnosis to day 0. At each time point 5 Â 10 6 leukemic cells were lyzed in 100 ml of lysis buffer (150 ml NaCl, 30 mM Tris (pH 7.6), 10% glycerol, 1% Triton X-100, 1 mM phenylmethylsulphonylfluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptine) for 15 min on ice. Cleared supernatants were stored at À80 1C until the time of analysis. The intracellular amounts of amino acids were expressed as mmol of amino acid per mg of protein. The lower limit of detection was 7 mmol (coefficient of variation 10%). Intracellular protein content was measured using the bicinchoninic acid assay (Interchim Omnilabo, Rockford, Illinois, USA 29 ). For ex vivo exposure to L-asparaginase, cells were incubated with culture medium as control or incubated with 0.1 or 10 IU/ ml of L-asparaginase (Paronal) in culture medium. A total of 5 Â 10 6 cells were harvested after 1, 3, 6, 24 and 30 h, and if possible after 48 and 72 h of incubation with L-asparaginase and amino-acid levels were analyzed.
Clinical toxicity
On the basis of clinical manifestations of diabetes mellitus, pancreatitis and hyperlipidemia, neurotoxicity and stroke laboratory parameters were monitored. Changes in coagulation and fibrinolysis were monitored throughout induction therapy. On days À5 and 0 and during induction on days 29, 33, 36, 40 and 43, peripheral blood samples were collected from the infusion line just before each Paronal infusion. All coagulation assays were performed with commercially available reagents and methods as described in detail previously. 30 Reference values were applied from the literature.
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Statistics
Differences between multiple groups were calculated using the Kruskal-Wallis test. The Mann-Whitney test was used when two groups were compared. P ¼ 0.05 (two sided) was used as level of significance.
Median follow-up time of patients at risk of an event was 4.1 years (range 1.9-5.5 years). Event-free survival (EFS) defined as relapse-free survival was calculated according to Kaplan-Meier ( ± s.e.). Multiple regression was conducted using Cox proportional hazards regression models to assess prognostic factors for EFS.
Results
Patients
Between July 2000 and July 2004, 57 children with newly diagnosed ALL were enrolled in the PEG-asparaginase-window study ( Table 1) . As only patients with initial WBC410 Â 10 9 per liter were eligible for this study, more than half of these children were high-risk patients according to ALL-9 criteria.
Clinical response
Administration of PEG-asparaginase at day À5 resulted in a steadily drop in the number of leukemic cells in the peripheral blood over 5 consecutive days. The median leukemic cell count was reduced 192-fold from 34.5 Â 10 9 per liter at day À5 to 0.18 Â 10 9 per liter at day 0 ( Figure 1 ). Out of 57, 35 (61%) children were defined as good responders to PEG-asparaginase, 16 (28%) were intermediate responders and 6 (11%) children were poor responders.
The good prognostic genotypes (hyperdiploid and TELAML1/ t(12;21)-positive ALL) were associated with a good clinical window response, whereas the poor prognostic genotype BCRABL/t(9;22) was associated with a poor clinical window response (P ¼ 0.04) ( Table 2 ). The 17 T-ALL patients had a significant poorer response to PEG-asparaginase compared to the 36 common/pre B cases (P ¼ 0.01), BCRABL patients were not included.
In vitro cytotoxicity of L-asparaginase was measured in 41 leukemic cell samples. Children with a poor or intermediate in vivo response to PEG-asparaginase treatment had a median LC 50 value of 1.0 IU/ml compared to 0.04 IU/ml for children with a good clinical response. So poor and intermediate responders were in vitro 25-fold more resistant to L-asparaginase (P ¼ 0.02) than children with a good in vivo response ( Figure 2 ). In concordance with earlier studies, 34 T-ALL cells were significantly more in vitro resistant to L-asparaginase than precursor B-ALL cells (LC 50 median 1.22 IU/ml versus 0.10 IU/ ml; Po0.001). Only one 8-year-old girl with T-ALL and an initial WBC of 132 Â 10 9 per liter had a poor clinical response (WBC 25 Â 10 9 per liter at day 0, absolute leukemic cell count 19.3 Â 10 9 per liter), whereas her blasts were in vitro sensitive to L-asparaginase. She still is in continuous complete remission.
Apoptosis
Analysis of in vivo induced apoptosis by PEG-asparaginase. We analyzed 25 patients for different apoptotic parameters over time ( Figure 3 ). At diagnosis samples from 13 patients were available, immediately after the PEG-asparaginase infusion samples from 21 patients, and on the consecutive days from 10 to 24 patients. The median percentage of ALL cells showing phosphatidylserine externalization was 10.5% before starting treatment (day À5). These values did not significantly differ over time ( Figure 3a ). The median percent of cells with changes in mitochondrial transmembrane potential was small at all time points: before PEG-asparaginase exposure 5.4% cells were DIOC6 positive, this did not change over time (P ¼ NS) (Figure 3b ). The median percentage of cells with cleaved (and hence activated) caspase 3 at diagnosis was 2.7% and remained low (P ¼ NS) (Figure 3c ). The median percent of cells with PARP inactivation at diagnosis was 2.9% and remained low (P ¼ NS) (Figure 3d ). These data show that the drop in WBC count and number of leukemic cells ( Figure 1 ) seen after PEG-asparaginase administration was not simultaneously associated with an increase in Analysis of in vitro induced apoptosis by L-asparaginase. In contrast to data obtained after in vivo exposure, significant changes in apoptotic parameters were detected after in vitro exposure to L-asparaginase ( Figure 3e ). This is in correspondance with earlier studies showing that activation of these apoptotic markers can be measured after in vitro exposure to L-asparaginase.
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L-asparaginase activity and levels of amino acids in serum
The median serum level of asparagine before treatment was 38.7 mM (p25th-75th: 28.1-44.9 mM). In all patients serum asparagine levels decreased below the limit of detection of 0.2 mM after the administration of PEG-asparaginase (Po0.001) (Figures 4a and b) . With the exception of two patients these asparagine levels remained below 0.2 mM until day 21, so for a total of at least 26 days. The L-asparaginase activity in the serum was 4100 IU/l for a total of at least 15 days (Figure 4a ). The level of serum aspartic acid (Figure 4b ) increased after 1 h of PEG-asparaginase infusion from 7.1 mM (p25th-75th: 4.1-14.3 mM) to 22.1 mM (p25th-75th: 15.5-47.3 mM) (Po0.001), followed by a decrease to median 11.7 (p25th-75th: 7.3-21.3 mM) and 15.5 mM (p25th-75th: 9.6-23.5 mM) at days À3 and 0. Compared to the level measured at diagnosis before the PEG-asparaginase infusion, the serum aspartic acid levels were still increased at both time points (P ¼ 0.02 at day -3) and (P ¼ 0.05 at day 0). Most glutamine levels stayed beyond the upper limit of detection (4250 mM) after PEG-asparaginase treatment (Figure 4b ). However, glutamic acid levels significantly increased from median 87.6 mM (p25th-75th: 57.8-124 mM) before treatment to 310 mM (p25th-75th: 178-396 mM) 1 h after therapy (Po0.001) and to 239 mM (p25th-75th: 125-306 mM) at day-3 (Po0.001) and 159 mM (p25th-75th: 127-300 mM) at day 0 (Po0.001) (Figure 4b) .
The serum peak levels of PEG-asparaginase did not differ between clinical response groups. No correlation with age, immunophenotype or WBC was observed.
Intracellular amino-acids levels
In vivo PEG-asparaginase exposure. Intracellular levels of 20 different amino acids were measured in leukemic cells of 19 children with newly diagnosed ALL and in peripheral blood cells of 9 healthy control children without bone marrow disease. The protein concentration of ALL cells was median 176 mg/ml (25th-75th percentile: 146-226 mg/ml) (N ¼ 9), which significantly differed from the protein content of mononuclear peripheral blood cells of normal controls (447 mg/ml; 25th-75th percentile: 347-568 mg/ml) (Po0.0001). The amino-acid levels were therefore expressed as mmol/mg of cellular protein.
The intracellular levels for 16 out of 20 amino acids did not differ between the ALL cells at diagnosis and normal controls (Table 3) . Aspartic acid (Po0.05), glutamic acid (Po0.05) and cystathionine (Po0.01) were twofold higher in ALL compared to normal controls, whereas taurine levels were 5.4-fold lower in leukemic cells (Po0.001). PEG-asparaginase did not affect the intracellular amino-acid levels over time (Table 3) , as is also shown in Figure 5a for asparagine, aspartic acid, glutamine and glutamic acid. The intracellular amino-acid levels at diagnosis and the in vivo response to PEG-asparaginase did not correlate ( Figure 6 ; Table 4 ). Results were borderline significant for leucine, but not significant if adjusted for multiple testing. One remarkable difference demonstrated valine, which was two times higher in nonresponding patients.
As amino-acid levels did not change over time, the relation between clinical response and amino-acid levels over time was not further evaluated.
In correspondence with the in vivo data, the levels of intracellular amino acids did not significantly differ between in vitro L-asparaginase-resistant and -sensitive patients (Table 4 ).
In vitro L-asparaginase exposure. In contrast to the lack of in vivo intracellular depletion of asparagine and glutamine (Figure 5a ), significant intracellular depletion was detected after in vitro exposure to L-asparaginase. Leukemic blasts of six patients were in vitro exposed to 0.1 IU/ml L-asparaginase, 10 IU/ml L-asparaginase and to culture medium only as control, and analyzed before exposure and during 72 h after exposure. Significant intracellular asparagine depletion was observed with 0.1 IU/ml and 10 IU/ml of L-asparaginase at all time points tested (Po0.05) (Figure 5b ). Only after exposure to 10 IU/ml of L-asparaginase, intracellular glutamine levels declined significantly within 3 h (Po0.001), whereas no significant rise in glutamic acid could be observed (Figure 5b ).
Clinical toxicity
No clinical toxicity related to PEG-asparaginase was seen during the window phase. At day 29 of the induction phase in which patients received twice-weekly Paronal, one patient out of 57 patients experienced a period of diabetes mellitus. No child demonstrated an allergic reaction to the first Paronal infusion on day 28. One out of 57 children had a grade 3 allergic reaction on the second infusion. Treatment was switched to Oncaspar and could not completely be finished. So 56/57 patients received the total of four Paronal doses during induction.
Of 30 high-risk patients, 1 relapsed within 2 months after diagnosis and changed protocol before the intensification phase. Of the remaining 29, 15 (52%) children demonstrated an allergic reaction. Moreover, 9 of these 15 could complete the intensification therapy by switching to Erwinase or to Oncaspar. The allergy rate of 52% was not higher than the 81% allergy rate in a group of 16 high-risk patients treated with the same ALL-9-HR protocol but without the upfront PEG-asparaginase window.
Changes in hemostasis.
At diagnosis data point to enhanced thrombin generation. Consumption coagulopathy was monitored in 17 patients (Table 5) .
On day 0, 5 days after the administration of 1000 IU/m 
Outcome and prognostic factors
Survival analysis of in vivo response to PEG-asparaginase showed that clinically good window responders had a more favorable outcome than clinically poor window responders (3-year EFS±s.e.: 91±6% for good, 81±10% for intermediate and 33 ± 19% for poor responders (median follow-up 4.1 years; Figure 4 (a) The effect of 1000 IU/m 2 PEG-asparaginase administered i.v. 5 days upfront regular chemotherapy on serum asparagine levels in time. The levels of PEG-Asparaginase (left Y-axis in IU/ml) are given in black, the levels of asparagine (right Y-axis in mM) in gray; 0.0001 mM is the detection limit of asparagine, the upper dotted line is the reference L-asparaginase activity level of 100 IU/ml. (b) Serum amino-acid levels of asparagine, aspartic acid, glutamine and glutamic acid were measured in 24 children with newly diagnosed ALL before and after in vivo administration of one dose of 1000 IU/m 2 PEG-Asparaginase. Significant changes between the levels at diagnosis and 1 h after the administration of PEG-asparaginase are indicated by Po0.001. i.v., intravenously; PEG, pegylated; ALL, acute lymphoblastic leukemia. Figure 7a ). The hazard ratio for the good and intermediate responders compared to the poor responders was 6.4 (95% CI 1.81-22.86) ( Table 6 ). The prognosis of good and intermediate responders was significantly higher than for the poor responder group (P ¼ 0.004, univariate analysis). The P-value of the trend analysis for all three groups was 0.014.
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Patients who were in vitro sensitive or intermediate sensitive to L-asparaginase had a 3-year EFS of 93 ± 7 and 100%, which is significantly different from the EFS of 53±13% for the in vitro resistant patients (Figure 7b ). The hazard ratio for the good and intermediate-sensitive patients compared to the resistant patients was 3.7 (95% CI 1.3-10.7; P ¼ 0.014) ( Table 6 ). The P-value of the trend analysis for all three groups was 0.16.
Of the other variables including age, sex, WBC, immunophenotype and genotype, only WBC (4or o50 Â 10 9 per liter) at diagnosis was significantly related to outcome in the Cox univariate analysis (P ¼ 0.02) ( Table 6) .
In a multivariate analysis, including clinical response, in vitro L-asparaginase resistance, age, white blood cell count and immunophenotype, only the clinical response was an independent risk factor (P ¼ 0.042) (w 2 -trend 6.602, P ¼ 0.0013).
Discussion
In the present study we investigated the effect of a therapeutic window with one single dose of PEG-asparaginase before start of combination chemotherapy on several pharmacodynamic and pharmacokinetic parameters, and on clinical response in pediatric ALL.
Clinical response
Monotherapy with 1000 IU/m 2 caused a gradual decrease of the leukemic cell burden in most patients within 5 days of treatment ( Figure 1 ). Children with unfavorable characteristics like T-ALL or BCRABL/t(9;22)-positive ALL were in vivo more resistant to PEG-asparaginase than children with a more favorable immunophenotype and genotype. This is in concordance with the fact that T-ALL cells were found to be in vitro more resistant to L-asparaginase. 34 For BCRABL/t(9;22), the in vivo resistance to L-asparaginase is a new finding. In the present study we also showed that in vitro resistance to L-asparaginase is related to the clinical response to PEG-asparaginase as single drug.
Parameters of apoptosis
Apoptotic markers at diagnosis did not predict the clinical response. We, like others 36 were not able to demonstrate a change in the percentage of in vivo apoptotic cells after administration of PEG-asparaginase. If however, ALL cells were in vitro exposed to L-asparaginase, a significant increase in time of the apoptotic markers was found, confirming previous findings. 19 Together with the fact that there was a rapid decrease in leukemic cells upon in vivo PEG-asparaginase exposure, these findings indicate that apparently no apoptotic cells remain in the circulation in vivo. Most likely, these apoptotic cells are rapidly being removed by phagocytosis.
37 Table 3 Effect of one single dose of PEG-asparaginase on intracellular amino-acid levels in newly diagnosed ALL Abbreviations: ALL, acute lymphoblastic leukemia; PEG, pegylated. Levels of 20 intracellular amino acids in mmol/mg cellular protein in leukemic blasts of 19 patients with ALL after one dose of PEG-asparaginase, compared to the levels in peripheral blood cells of nine normal controls. Data are given as medians with interquartile ranges. The amino acids that demonstrate significant different levels compared to normal are given in bold. Superscripts refer to P-values: The effect of in vitro exposure to L-asparaginase on intracellular amino-acid levels of asparagine, aspartic acid, glutamine and glutamic acid of leukemic cells of six patients that were in vitro exposed to 10 IU/ml L-asparaginase. Asparagine levels (Po0.05) and glutamine levels (Po0.001) decreased significantly before and after incubation with L-asparaginase. ALL, acute lymphoblastic leukemia; PEG, pegylated.
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L-asparaginase activity in serum and intracellular amino acids
One dose of 1000 IU/m 2 PEG-asparaginase immediately resulted in complete serum asparagine depletion with a concomitant rise in serum aspartic acid and glutamic acid. Our data are in correspondence with previous data observed in a larger group of patients treated with L-asparaginase and confirm that PEG-asparaginase will yield its pharmacodynamic effects for 2-4 weeks. 38 However, in vivo no changes were observed in the levels of intracellular amino acids (including asparagine, aspartic acid, glutamine and glutamic acid) directly after PEG-asparaginase administration nor on successive days thereafter, except for valine. So far, no explanation can be given for the high level of valine in the nonresponding group. In contrast, in vitro exposure to L-asparaginase of ALL cells significantly changed the intracellular asparagine and glutamine levels that reflected the changes observed in serum suggesting that the surviving leukemic cells are capable of keeping the intracellular amino-acid pools in balance, whereas those cells that are not capable of doing so die and are immediately removed from the blood circulation. Therefore the in vivo process of intracellular amino-acid depletion in leukemic cells Figure 6 Intracellular amino-acid levels (in mmol/mg of intracellular protein) of asparagine, aspartic acid, glutamine and glutamic acid at diagnosis of 19 children with ALL, related to their clinical response to one dose of 1000 IU/m 2 PEG-asparaginase 5 days later, as defined in figure 1 . ALL, acute lymphoblastic leukemia; PEG, pegylated.
Table 4
Intracellular amino-acid levels at diagnosis related to in vitro and in vivo sensitivity Table 5 Coagulation parameters of 57 patients before the window with PEG-asparaginase at day -5, before starting ALL-9 induction therapy (day 0) and during four Paronal infusions cannot be measured which is in correspondence with the finding that no in vivo effect on apoptosis parameters could be measured. These data underline the fact that only in vitro studies have been published that show a relationship between aminoacid depletion and apoptosis, 39, 40 whereas literature on in vivo measurements is lacking.
Essential amino acids
Iwamoto et al. 41 recently described the protective effect of mesenchymal cells in L-asparaginase cytotoxicity. They postulated that the interaction between ALL cells and the microenvironment in which these cells reside protected the leukemic cells from asparagine depletion by a high expression of asparagine synthetase in these mesenchymal cells. Surviving leukemic cells may therefore be rescued with asparagine produced by mesenchymal cells. There was no correlation between the upregulation of asparagine synthetase mRNA and the amount of asparagine in the leukemic cells (data not shown). At present protection of ALL cells from L-asparaginase toxicity by mesenchymal cells is part of an ongoing debate.
Another possible explanation for the discrepancy of cellular asparagine levels in vivo and in vitro comes from the Italian group of Bussolati. 42, 43 In vitro L-asparaginase rapidly hydrolyzes asparagine and subsequently glutamine if asparagine is depleted. 44 As the main amino group for in vivo asparagine synthesis is provided by glutamine, depletion of glutamine impacts endogenous asparagine synthesis. However, glutamine is abundantly present in vivo, and hence a donor for the amino group needed for asparagine synthesis is not lacking. This theory might also explain our finding that asparagine remains detectable in leukemic blasts after in vivo exposure to PEGasparaginase. Not only Boos et al. 44 but also Fine et al. 45 emphasized the fact that leukemic cell lines and primary samples from leukemic patients are different from each other and cell line data cannot be extrapolated to primary patients' samples that easily. At diagnosis the intracellular levels of glutamic acid and cystathionine were higher and taurine levels were lower in leukemic cells compared to normal peripheral blood mononuclear cells. Proliferating leukemic cells may produce more glutamic acid due to a fast turnover of glutamine to provide nitrogen and carbon needed for the synthesis of purines and pyrimidines energy metabolism. 46 It is known that malignant cells are more dependent on an exogenous source of asparagine and glutamine than normal cells. 47 The high levels of cystathionine and low levels of taurine may be linked to each other. Leukemic cells were shown to have consistently lower taurine levels compared to normal lymphocytes and granulocytes. 48 A low activity of g-cystathionase in leukemic cells might result in an abnormal methionine-cysteine pathway leading to higher levels of its starting product cystathionine and lower levels of the end product taurine.
Chakrabarti et al. 49 also tried to explain differences in L-asparaginase resistance by differences in intracellular aminoacid metabolism. They pointed to a hypothesis of Ryan and Keefer, that depletion of asparagine might result in decreased glycine and serine concentrations in L-asparaginase-sensitive but not in L-asparaginase-resistant tumor cells. 50, 51 Asparagine is required for the transamination of glyoxylate resulting in glycine and serine depletion, which could have severe consequences for purine biosynthesis. 49 However, we did not find evidence to support these hypotheses as we found no difference in the serine or glycine content between in vivo good and poor responders to L-asparaginase nor between in vitro L-asparaginase-sensitive and -resistant leukemic cells.
It has also been suggested that L-asparaginase treatment caused reduced incorporation of valine into proteins in L-asparaginase-sensitive cells but not in L-asparaginase-resistant tumor cells. 52 In our group valine levels before L-asparaginase treatment were two times lower in in vivo good/intermediate responders compared to poor responders. However, no difference in the level of valine between in vitro L-asparaginase-resistant and -sensitive ALL cells were observed in the present study.
Clinical toxicity, allergic reactions and changes in hemostasis
There was no acute toxicity of one dose of PEG-asparaginase in this investigational window. One extra dose of PEG-asparaginase did not lead to higher incidence of allergic reactions during induction treatment and also not during intensification therapy 3 months later. This is of importance as Silverman et al. observed that L-asparaginase tolerance is an important prognostic factor in ALL. 2 The single dose of PEG-asparaginase in this study induced a fall in more than half of the coagulation proteins. We demonstrated that the serum asparagine depletion due to one PEG-asparaginase infusion of 1000 IU/m 2 lasted about 4 weeks. This did not result in a persistent inhibition of coagulation protein synthesis. At day 29, so almost 5 weeks after PEG-asparaginase administration, all coagulation parameters had recovered to normal or even increased levels. The levels of all coagulation parameters were in the same range as published recently in children treated with the same protocol without the PEG-asparaginase window. 35 Disturbances in hemostasis due to amino-acid depletion are probably a local effect, that is, in the liver only. 53, 54 Outcome and prognostic factors Both the clinical response to PEG-asparaginase window and the in vitro sensitivity to L-asparaginase are predictive for outcome. The prognostic relevance of the in vitro sensitivity has been previously shown. [5] [6] [7] [8] In the present study we also show that the in vivo response to a window with L-asparaginase predicts outcome, which is in concordance with the data of Asselin et al. 9 These results suggest that children with ALL with a poor clinical response to PEG-asparaginase might benefit from a more intensive antileukemic therapy.
Conclusion
The clinical response to one dose of 1000 IU/m 2 PEGasparaginase intravenously as an investigational window is an independent prognostic marker related to outcome. Children with the favorable common/pre B ALL especially those with TELAML1 positivity and hyperdiploidy show a good clinical response to PEG-asparaginase and children with the prognostic unfavorable factors T-cell immunophenotype or BCRABL/t(9;22) have a relatively poor response to PEG-asparaginase. The in vivo response to PEG-asparaginase correlates well with in vitro sensitivity to L-asparaginase. Intracellular changes in apoptotic features and amino acids in ALL cells cannot be monitored in vivo; this may be explained by the fact that apoptotic cells are immediately removed from the circulation by phagocytosis. Otherwise it is possible that in vivo mesenchymal cells from the bone marrow supply leukemic blasts with asparagine in response to treatment with L-asparaginase. Intracellular aminoacid concentrations at diagnosis are not related to PEGasparaginase response. One additional dose of PEG-asparaginase proved to be safe in children with ALL because it did not cause a higher incidence of allergic reactions to L-asparaginase further on in treatment and it caused no severe toxicities.
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